Roche Molecular Diagnostics, 4300 Hacienda Drive, Pleasanton, CA 94588, USA.
Future Oncol. 2016 Feb;12(4):451-2. doi: 10.2217/fon.15.311. Epub 2016 Feb 3.
Paul Brown speaks to Gemma Westcott, Commissioning Editor: Paul Brown has served as the Head of Roche Molecular Diagnostics at Roche Diagnostics Corporation since February 2010 having previously held a variety of positions within Roche Pharma. After completing his doctorate in organic chemistry he was awarded a post-doctoral fellowship at the California Institute of Technology in Pasadena, CA, USA, but soon returned to his native UK to join Roche Pharma Research. Paul's first post within Roche was as group leader, doing drug discovery and making new small molecule drugs, but later moved into the business part of the company. Since then, he has enjoyed roles such as lifecycle leader for brands such as Tamiflu(®) and Xenical, vice president of sales and marketing of the pharmaceutical division and most recently general manager of Roche Pharma, Sweden.
保罗·布朗接受了 Gemma Westcott 的采访,Gemma Westcott 是罗氏诊断公司的医药编辑:保罗·布朗自 2010 年 2 月起担任罗氏分子诊断部主管,在此之前,他在罗氏制药公司担任多个职位。在完成有机化学博士学位后,他在美国加州帕萨迪纳的加州理工学院获得了博士后奖学金,但很快回到了他的祖国英国,加入了罗氏制药公司。保罗在罗氏的第一份工作是担任组长,从事药物发现和新型小分子药物的研发,但后来进入了公司的业务部门。从那时起,他曾担任过多个职位,如达菲(Tamiflu)和赛尼可(Xenical)等品牌的生命周期主管、制药部门的销售和市场副总裁,以及最近的罗氏制药公司瑞典总经理。